Evaluation of Genistein Effect on Invasion of Breast Cancer Stem Cell-Like Cells
It is established that cancer stem cells (CSCs) have potential in tumor formation, progression, and metastasis in different types of solid tumors. Additionally, recent studies have demonstrated that Genistein consumption is correlated with lowered cancer rate and metastasis decrease. In this study, we premised that Genistein could be an influential agent targeting breast cancer stem cell-like cells. In this survey, CD44+/CD24-cells (cancer stem cell-like cells) were isolated from MDA-MB-231 cells by magnet-activated cell sorting (MACS). The effect of various concentrations of Genistein on the cell proliferation and viability in MDA-MB-231 CD44+/CD24-cells tested in comparison to their parental cells utilizing MTT assay, invasion assay. The results of this study show that Genistein could inhibit invasion in MDA-MB-231 cells. Also, we observed that Genistein could be efficient for invasion inhibition in CD44+/CD24-cells. Considering the finding that Genistein could have desired effects on MDA-MB-231 as well as CD44+/CD24-cells, we demonstrated that Genistein could be an influential agent for treating malignant and invasive breast tumors.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-8.
Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005;45(8):872-7.
Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004;23(43):7274-82.
Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutrition and cancer.2006;55(1):1-12.
Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer and Metastasis Reviews. 2010;29(3):465-82.
Lee HP, Lee J, Gourley L, Duffy SW, Day NE, Estève J. Dietary effects on breast-cancer risk in Singapore. The Lancet. 1991;337(8751):1197-200.
Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutrition and cancer. 2009;61(5):598-606.
Andersen OM, Markham KR. Flavonoids: chemistry, biochemistry and applications: CRC Press; 2005.
Farsandaj N, Ghahremani MH, Ostad SN. Role of cannabinoid and vanilloid receptors in invasion of human breast carcinoma cells. Journal of Environmental Pathology, Toxicology and Oncology. 2012;31(4).
Chinchar E, Makey KL, Gibson J, Chen F, Cole SA, Megason GC, et al. Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc Cell. 2014;6:12.
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell stem cell. 2007;1(5):555-67.
Hwang-Verslues WW, Kuo W-H, Chang P-H, Pan C-C, Wang H-H, Tsai S-T, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PloS one. 2009;4(12):e8377.
Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000;95(3):952-8.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. science. 1999;284(5411):143-7.
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer research. 2003;63(18):5821-8.
Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008;10(1):R10.
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem cell reports. 2014;2(1):78-91.
Yan W, Chen Y, Yao Y, Zhang H, Wang T. Increased invasion and tumorigenicity capacity of CD44+/CD24-breast cancer MCF7 cells in vitro and in nude mice. Cancer Cell Int. 2013;13(1):62.
Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25(15):2273-84.
Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8(5):R59.
Behbod F, Rosen JM. Will cancer stem cells provide new therapeutic targets? Carcinogenesis. 2005;26(4):703-11.
Conklin CMJ, Bechberger JF, MacFabe D, Guthrie N, Kurowska EM, Naus CC. Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells. Carcinogenesis. 2006;28(1):93-100.
Horia E, Watkins BA. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis. 2006;28(4):809-15.